Division of HPB and Transplant Surgery, Department of Surgery, Erasmus MC Transplant Institute, Erasmus University Medical Center, Rotterdam, The Netherlands.
Department of Surgery, LUMC Transplant Center, Leiden University Medical Center, Leiden, The Netherlands.
Ann Surg. 2022 Oct 1;276(4):e223-e230. doi: 10.1097/SLA.0000000000005611. Epub 2022 Jul 21.
This study investigates whether liver grafts donated after circulatory death (DCD) that are declined by the entire Eurotransplant region can be salvaged with abdominal normothermic regional perfusion (aNRP).
aNRP is increasingly used for DCD liver grafts because it prevents typical complications. However, it is unclear whether aNRP is capable to rescue pretransplant declined liver grafts by providing the opportunity to test function during donation.
Donor livers from DCD donors, declined by all centers in the Eurotransplant region, were included for this study. The comparator cohort included standard DCD livers and livers donated after brain death, transplanted in the same time period.
After the withdrawal of life-sustaining treatment, 28 from the 43 donors had a circulatory death within 2 hours, in which case aNRP was initiated. Of these 28 cases, in 3 cases perfusion problems occurred, 5 grafts were declined based on liver assessment, and 20 liver grafts were transplanted. The main differences during aNRP between the transplanted grafts and the assessed nontransplanted grafts were alanine transaminase levels of 53 U/L (34-68 U/L) versus 367 U/L (318-488 U/L) ( P =0.001) and bile production in 100% versus 50% of the grafts ( P =0.024). The 12-month graft and patient survival were both 95%, similar to the comparator cohort. The incidence of ischemic cholangiopathy was 11%, which was lower than in the standard DCD cohort (18%).
aNRP can safely select and thus is able to rescue DCD liver grafts that were deemed unsuitable for transplantation, while preventing primary nonfunction and minimizing ischemic cholangiopathy.
本研究旨在探讨通过腹部常温区域灌注(aNRP)是否可以挽救整个欧洲器官移植区域拒绝的循环死亡(DCD)供体的肝移植物。
aNRP 越来越多地用于 DCD 肝移植物,因为它可以预防典型的并发症。然而,尚不清楚 aNRP 是否能够通过提供在捐赠期间测试功能的机会来挽救移植前拒绝的肝移植物。
本研究纳入了来自 DCD 供体的肝移植物,这些供体已被欧洲移植区域的所有中心拒绝。对照组包括同期移植的标准 DCD 肝和脑死亡供体的肝。
在停止维持生命的治疗后,43 名供体中有 28 名在 2 小时内发生循环死亡,此时开始进行 aNRP。在这 28 例中,有 3 例出现灌注问题,根据肝脏评估拒绝了 5 例移植物,而移植了 20 例肝移植物。在 aNRP 期间,移植的移植物与评估未移植的移植物之间的主要差异是丙氨酸转氨酶水平分别为 53 U/L(34-68 U/L)和 367 U/L(318-488 U/L)(P = 0.001),以及 100%和 50%的移植物产生胆汁(P = 0.024)。12 个月的移植物和患者存活率均为 95%,与对照组相似。缺血性胆管炎的发生率为 11%,低于标准 DCD 队列(18%)。
aNRP 可以安全地选择并因此能够挽救被认为不适合移植的 DCD 肝移植物,同时预防原发性无功能并最大限度地减少缺血性胆管炎。